Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
The Role of Fibrosis and Metformin in BRCA-mutant ovaries
EF 2022-23
Résumé
The most lethal gynecological malignancy is ovarian cancer, with a 5-year survival rate of approximately 45% (1). Established risk factors for ovarian cancer are ovulation and age, which are non-hereditary, and hereditary factors such as BRCA1 mutations. The Vanderhyden lab found a relationship between fibrosis and age due to extracellular matrix remodelling and the ordered arrangement of collagen in human (2,3) and mice (4) ovaries. Preliminary studies show that women with BRCA1 mutations develop fibrotic ovaries pre-menopause compared to non-carriers. The exact mechanism for the accelerated fibrosis in BRCA1 carriers has not been elucidated; therefore, the Vanderhyden lab has developed and isolated culture mouse ovarian fibroblasts (MOFs) from floxed mice homozygous or heterozygous for the deletion of BRCA1. We hypothesize an increase in structural proteins, such as collagen, in BRCA1 mutants, accelerating ovarian fibrosis and cancer risk. My first aim is to determine if BRCA2 deficiency hyperactivate ovarian fibrosis. I then plan to determine the effects of Brca1 mutations on fibroblast activation in vivo. My final aim is asses whether metformin can abrogate Brca1-associated fibrosis. Future results will elucidate whether metformin can inhibit fibrosis in Brca1 carriers leading to additional studies to determine metformin’s potential as a prophylactic to delay or prevent the onset of ovarian cancer.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
490913
Name
Piccolo Olivia R
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The Role of Fibrosis and Metformin in BRCA-mutant ovaries
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Brca Mutations; Cancer Prevention; Fibrosis; Ovarian Cancer
Abstract
The most lethal gynecological malignancy is ovarian cancer, with a 5-year survival rate of approximately 45% (1). Established risk factors for ovarian cancer are ovulation and age, which are non-hereditary, and hereditary factors such as BRCA1 mutations. The Vanderhyden lab found a relationship between fibrosis and age due to extracellular matrix remodelling and the ordered arrangement of collagen in human (2,3) and mice (4) ovaries. Preliminary studies show that women with BRCA1 mutations develop fibrotic ovaries pre-menopause compared to non-carriers. The exact mechanism for the accelerated fibrosis in BRCA1 carriers has not been elucidated; therefore, the Vanderhyden lab has developed and isolated culture mouse ovarian fibroblasts (MOFs) from floxed mice homozygous or heterozygous for the deletion of BRCA1. We hypothesize an increase in structural proteins, such as collagen, in BRCA1 mutants, accelerating ovarian fibrosis and cancer risk. My first aim is to determine if BRCA2 deficiency hyperactivate ovarian fibrosis. I then plan to determine the effects of Brca1 mutations on fibroblast activation in vivo. My final aim is asses whether metformin can abrogate Brca1-associated fibrosis. Future results will elucidate whether metformin can inhibit fibrosis in Brca1 carriers leading to additional studies to determine metformin’s potential as a prophylactic to delay or prevent the onset of ovarian cancer.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Piccolo, Olivia R
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~